Nrx Pharmaceuticals (Nasdaq:NRXP) Confirms Path To New Drug Application With Real World Data And Broader Proposed Indication For NRX-100 (Ketamine) Following Type C FDA Meeting March 17, 2026 depression ONLY AVAILABLE IN PAID PLANS. Originally reported by menafn. Read more Source: https://menafn.com/1110866066/Nrx-Pharmaceuticals-NasdaqNRXP-Confirms-Path-To-New-Drug-Application-With-Real-World-Data-And-Broader-Proposed-Indication-For-NRX-100-Ketamine-Following-Type-C-FDA-Meeting
